skip to main
|
skip to sidebar
InviGoBlog
Paid To Popup
Tuesday, January 15, 2008
Nissen Weighs in on ENHANCE
You know what he's going to say ...
Remind you of this?
Newer Post
Older Post
Home
Blog Archive
►
2011
(371)
►
October
(27)
►
September
(27)
►
August
(23)
►
July
(37)
►
June
(30)
►
May
(31)
►
April
(46)
►
March
(55)
►
February
(49)
►
January
(46)
►
2010
(520)
►
December
(52)
►
November
(32)
►
October
(26)
►
September
(34)
►
August
(30)
►
July
(43)
►
June
(41)
►
May
(52)
►
April
(53)
►
March
(50)
►
February
(46)
►
January
(61)
►
2009
(463)
►
December
(65)
►
November
(26)
►
October
(26)
►
September
(26)
►
August
(24)
►
July
(30)
►
June
(39)
►
May
(53)
►
April
(35)
►
March
(51)
►
February
(40)
►
January
(48)
▼
2008
(482)
►
December
(42)
►
November
(28)
►
October
(36)
►
September
(35)
►
August
(26)
►
July
(52)
►
June
(40)
►
May
(35)
►
April
(44)
►
March
(41)
►
February
(52)
▼
January
(51)
"Consensus is not our goal": A Conversation with F...
Neuro Companies Causing Headaches
Who's Sorry Now? Not Feeling So Good Edition
A Mission at Risk
Close But No Cigar
Survey Says?! Too Little, Too Late
The Muddy Waters of IVD
Big Biotech M&A: Waiting for the Casus belli
Icahn to Biogen: Take a Mulligan
While You Were Almost Upsetting
FDA Gets Out in Front on Vytorin, Defends LDL Endp...
Deals of the Week: Beyond Vytoringate
The Best Defense Is a Good Offense, Or Something L...
Listen for the Threat of the Medicare Rebate
J&J Tests FDA's Pain Threshold with Tapentadol
Cardiovascular Systems Antes Up
Vytorin: Two Sources of Angst for DTC
Teva Buys Cogenesys
Ventana Accepts $3.4 Billion
Aye for an Eye
Vytorin: In this Case, Best to Ignore History
While You Were Losing Your Resolve
Deals of the Week: You Can't Always Get What You Want
Whose Life is it Anyway?
Bio-Rad Salutes You
Private Equity Goes Public
The Big Winner in the Vytorin Debacle? It Might be...
Orion to Cover Both Sides of the Atlantic
The Man Pharma Loves to Hate
Nissen Weighs in on ENHANCE
Lesson from the JPMorgan Conference: Exceptions Th...
Novo Scraps Inhaled Insulin
At JP Morgan, Stryker's Big Smile
Public Confidence in Drug Safety: Solution is in "...
While You Were Staying Put
Deals of the Week: far from the Westin St. Francis
Amgen Braces for Another Review of EPO Safety: How...
Biotech’s Original Sin
The R&D Productivity Crisis: Is There a Bright Side?
DTC User Fees Shot Down; Advertisers Face More Per...
Iowans Fall for Obama, Will New Hampshireites?
“We’re a Buyer, not a Seller,” Says Genzyme With I...
The Stakes Increase on Comparative Effectiveness
While You Were Going to California
Regulatory Sausage Making
Deals of the Week: New Year's Resolutions
Another Dismal Year for New Drug Approvals
Addex Ups Dealmaking Ante
Congress Has Lump of Coal for FDA in Funding Bill
New Year's Resolution 2008: Create Infrastructure ...
The Top Ten IN VIVO Blog Posts of 2007
►
2007
(182)
►
December
(32)
►
November
(42)
►
October
(37)
►
September
(33)
►
August
(29)
►
July
(9)
Followers
Total Pageviews